Suppr超能文献

具有强大传播阻断能力的新型青蒿素联合疗法的最佳10-氨基青蒿素——对包括KI3 C580Y突变体在内的血液期和肝期寄生虫的活性

Optimal 10-Aminoartemisinins With Potent Transmission-Blocking Capabilities for New Artemisinin Combination Therapies-Activities Against Blood Stage Including KI3 C580Y Mutants and Liver Stage Parasites.

作者信息

Wong Ho Ning, Padín-Irizarry Vivian, van der Watt Mariëtte E, Reader Janette, Liebenberg Wilna, Wiesner Lubbe, Smith Peter, Eribez Korina, Winzeler Elizabeth A, Kyle Dennis E, Birkholtz Lyn-Marie, Coertzen Dina, Haynes Richard K

机构信息

Centre of Excellence for Pharmaceutical Sciences, Faculty of Health Sciences, North-West University, Potchefstroom, South Africa.

Center for Tropical & Emerging Global Diseases, Coverdell Center, University of Georgia, Athens, GA, United States.

出版信息

Front Chem. 2020 Jan 10;7:901. doi: 10.3389/fchem.2019.00901. eCollection 2019.

Abstract

We have demonstrated previously that amino-artemisinins including artemiside and artemisone in which an amino group replaces the oxygen-bearing substituents attached to C-10 of the current clinical artemisinin derivatives dihydroartemisinin (DHA), artemether and artesunate, display potent activities against the asexual blood stages of (). In particular, the compounds are active against late blood stage gametocytes, and are strongly synergistic in combination with the redox active drug methylene blue. In order to fortify the eventual selection of optimum amino-artemisinins for development into new triple combination therapies also active against artemisinin-resistant mutants, we have prepared new amino-artemisinins based on the easily accessible and inexpensive DHA-piperazine. The latter was converted into alkyl- and aryl sulfonamides, ureas and amides. These derivatives were screened together with the comparator drugs DHA and the hitherto most active amino-artemisinins artemiside and artemisone against asexual and sexual blood stages of and liver stage () sporozoites. Several of the new amino-artemisinins bearing aryl-urea and -amide groups are potently active against both asexual, and late blood stage gametocytes (IC 0.4-1.0 nM). Although the activities are superior to those of artemiside (IC 1.5 nM) and artemisone (IC 42.4 nM), the latter are more active against the liver stage sporozoites (IC artemisone 28 nM). In addition, early results indicate these compounds tend not to display reduced susceptibility against parasites bearing the Kelch 13 propeller domain C580Y mutation characteristic of artemisinin-resistant . Thus, the advent of the amino-artemisinins including artemiside and artemisone will enable the development of new combination therapies that by virtue of the amino-artemisinin component itself will possess intrinsic transmission-blocking capabilities and may be effective against artemisinin resistant falciparum malaria.

摘要

我们之前已经证明,氨基青蒿素,包括青蒿酰胺和青蒿酮,其中一个氨基取代了当前临床青蒿素衍生物双氢青蒿素(DHA)、蒿甲醚和青蒿琥酯中与C-10相连的含氧取代基,对()的无性血液阶段显示出强大的活性。特别是,这些化合物对晚期血液阶段的配子体有活性,并且与氧化还原活性药物亚甲蓝联合使用时具有很强的协同作用。为了加强最终选择最佳的氨基青蒿素以开发成新的三联联合疗法,该疗法对青蒿素抗性突变体也有活性,我们基于易于获得且价格低廉的DHA-哌嗪制备了新的氨基青蒿素。后者被转化为烷基和芳基磺酰胺、脲和酰胺。这些衍生物与对照药物DHA以及迄今为止活性最高的氨基青蒿素青蒿酰胺和青蒿酮一起,针对()的无性和有性血液阶段以及肝期子孢子进行了筛选。几种带有芳基脲和酰胺基团的新氨基青蒿素对无性和晚期血液阶段的配子体都有很强的活性(IC 0.4-1.0 nM)。尽管这些活性优于青蒿酰胺(IC 1.5 nM)和青蒿酮(IC 42.4 nM),但后者对肝期子孢子更有活性(IC青蒿酮28 nM)。此外,早期结果表明这些化合物对携带青蒿素抗性()特征性的Kelch 13螺旋桨结构域C580Y突变的寄生虫往往不会表现出敏感性降低。因此,包括青蒿酰胺和青蒿酮在内的氨基青蒿素的出现将使开发新的联合疗法成为可能,凭借氨基青蒿素成分本身,这些联合疗法将具有内在的传播阻断能力,并且可能对青蒿素抗性恶性疟有效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5dc3/6967409/5a81624af85f/fchem-07-00901-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验